Stocks · News reference

Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Aug 26, 2026, 5:59 PMBenzinga Newsdesk

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 31, 2026, 9:21 PMSEC EDGAR
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-08-31 AccNo: 0001193125-26-377073 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
JAZZ
BenzingaAug 31, 2026, 5:27 PMBenzinga Newsdesk
Jazz Pharmaceuticals shares are trading higher after the company announced second interim top-line overall survival results from the Phase 3 HERIZON-GEA-01 trial.
JAZZ
BenzingaAug 31, 2026, 10:04 AMBenzinga Newsdesk
Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial
JAZZ
BenzingaAug 27, 2026, 6:23 AMBenzinga Newsdesk
Jazz Pharmaceuticals Prices Upsized $1.1B Offering Of 1.875% Exchangeable Senior Notes Due 2032, Announces $225.0M Concurrent Share Repurchase At $249.29 Per Share
JAZZ